Merck is relocating its U.S. Healthcare headquarters from Rockland, Massachusetts, to Boston’s Seaport district, the company announced this week.
The move, first reported by CHEManager, positions EMD Serono, Merck’s U.S. And Canadian healthcare business, within a leading life sciences hub. According to Chris Round, president of EMD Serono, the relocation is a “milestone” in the company’s efforts to address unmet medical needs and support future growth. “The US market is critical to our continued success as a global specialty innovator,” Round said in a statement.
Merck plans to introduce one novel product or major indication every 1.5 years, beginning with potential launches in 2025 across neurology and immunology, oncology and fertility. The company’s global research and development hub will remain in Billerica, Massachusetts.
The Boston area is already a significant center for Merck’s research operations. The company’s Boston site focuses on discovery research in immunology, oncology, diabetes, and neuroscience, according to Merck. The Cambridge, Massachusetts, location concentrates on early-stage discovery research.
The U.S. Healthcare headquarters relocation is scheduled to be completed this summer. The company is currently hiring for positions at the Boston location, including a US Oncology Portfolio Marketing Manager, a hybrid role responsible for managing HCP and patient engagement contracting, national advisory board operations, and budget management.